Custom Gene-Targeting drug tested in single child with rare brain disease

NCT ID NCT07410143

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a custom-made drug called an antisense oligonucleotide (ASO) designed for one child with a rare, severe genetic brain disorder. The drug aims to correct the specific genetic mistake causing the disease. The trial focuses on safety and how the drug moves through the body, with only one participant enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

individualized antisense oligonucleotide (ASO)

What this could lead to

If successful, this approach could point toward a way to treat rare genetic brain diseases by correcting the specific genetic error in each patient.

What could go wrong

This is a very early trial with only 1 participant, so results may not apply to others. The treatment is experimental and may cause side effects or not work at all.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC CNS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Great Ormond Street Hospital

    London, United Kingdom